Abstract: Provided are a compound represented by the following Formula I, or a solvate, stereoisomer, or pharmaceutically acceptable salt thereof, and a composition for preventing or treating hair loss, the compound including the compound as an active ingredient:

Abstract: Provided are a compound represented by the following Formula I-1 or I-2, and a composition for preventing or treating dementia or Alzheimer's disease, the composition including the compound and a pharmaceutically acceptable carrier:

Abstract: A pretreatment method for analyzing dioxin compounds and an analytical method using the same, in which a column packed with polymer beads that are capable of selectively adsorbing dioxin compounds is used in a purification step during pretreatment, thereby remarkably reducing a time required for pretreatment and improving a recovery rate of an internal standard for purification, are provided.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.

Abstract: The present disclosure is related to an optical encoder which is configured to provide precise coding reference data by feature recognition technology. To apply the present disclosure, it is not necessary to provide particular dense patterns on a working surface. The precise coding reference data can be generated by detecting surface features of the working surface.

Abstract: A compound of Chemical Formula 1, and an organic photoelectric device, an image sensor, and an electronic device including the same are disclosed: In Chemical Formula 1, each substituent is the same as described in the detailed description.

Abstract: This invention relates to an automobile wheel having a vibration damping function. The automobile wheel includes a disk member connected with an axle hub and a rim member for mounting a tire. A hub cap is to be attached to or detached from one side of the disk member. A vibration damping plate in a shape corresponding to the hub cap is placed on one side of the hub cap to be in contact with the disk member. Vibration damping bushings are positioned at the vibration damping plate to be in contact with the disk member. The vibration damping plate and vibration damping bushings work together to attenuate vibration of the wheel.

Abstract: A vertical memory device and method of manufacture thereof are provided. The vertical memory device includes gate electrode layers stacked on a substrate; a channel layer penetrating through the gate electrode layers; and a first epitaxial layer in contact with a lower portion of the channel layer and including a region having a diameter smaller than an external diameter of the channel layer.

Abstract: The present invention is directed to compounds of generic formula (I): or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. The invention is further directed to methods of treating a patient (preferably a human) for diseases or disorders in which the A2A-receptor is involved. The invention further involves use of the compounds as an A2A-receptor antagonist and/or inhibitor for the preparation of a medicament for the treatment and/or prevention of diseases associated with inhibiting the receptor, which includes central nervous system disorders such as Parkinson's disease. The invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

Abstract: A semiconductor device includes a memory cell region including memory cells arranged along channel holes, the channel holes being provided on a substrate to extend in a direction perpendicular to an upper surface of the substrate, and a peripheral circuit region disposed outside of the memory cell region and including low voltage transistors and high voltage transistors, The low voltage transistors include first transistors including a first gate dielectric layer and a first gate electrode layer including a metal, and the high voltage transistors include second transistors including a second gate dielectric layer having a dielectric constant lower than a dielectric constant of the first gate dielectric layer, and a second gate electrode layer including polysilicon.

Abstract: A light-emitting diode includes: a gallium nitride substrate; a first semiconductor layer disposed thereon; a mesa including a second semiconductor layer disposed on the first semiconductor layer and an intervening active layer; a first contact layer including an outer contact part in contact with the first semiconductor layer near an edge of the substrate and an inner contact part in contact with the first semiconductor layer within a region encompassed by the outer contact part; a second contact layer disposed on the mesa in contact with the second semiconductor layer; an upper insulation layer having first and second opening parts overlapping the first and second contact layers; and first and second electrode pads electrically connected to the first and second contact layers through the first and second opening parts, wherein the LED can be driven at 150 A/cm2 or more and has a maximum junction temperature of 180° C. or more.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.

Abstract: The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.

Abstract: Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein “R1”, “RA-1”, “R2”, “R3”, and “Het” are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

Abstract: Provided are an light scanning device capable of adjusting the position of optics and an image forming apparatus including the light scanning device. The light scanning device includes first and second light sources configured to emit first and second light beams, respectively; optics including first and second lenses for transmitting the first and second light beams therethrough and a lens holder configured to support the second lens; and a housing configured to support the first and second light sources and the optics, wherein the first and second light sources and the first lens are supported to be fixed to the housing, and the second lens is supported to be able to move with respect to the first lens.

Abstract: The present invention provides a compound of Formula (I) and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds and said stereoisomers, and pharmaceutical compositions thereof, and methods for using said compounds and compositions for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Abstract: A vertical stack memory device includes a doped semiconductor substrate having a common source to which a source power is applied and a low band gap layer that is spaced apart from the common source, and the low band gap comprising low band gap materials. A stack gate structure has gate electrodes and insulation interlayer patterns that are alternately and vertically stacked on the substrate in a first direction. A channel structure penetrates through the stack gate structure in the first direction. The channel structure makes contact with the low hand gap layer. A charge storage structure is interposed between the stack gate structure and the channel structure. The charge storage structure is configured to selectively store charge and to provide the stored charge to a memory cell, the stack gate structure, and the channel structure.

Abstract: A semiconductor device includes first and second active regions extending in a first direction on a substrate and spaced apart from each other in a second direction intersecting the first direction, wherein the first and second active regions overlaps with each other in the second direction, a third active region extending in the first direction on the substrate and spaced apart from the first active region in the second direction. The first active region is positioned between the second and third active regions in the second direction. The first and third active regions partially overlap in the second direction, and a device isolation film is configured to define the first to third active regions.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more compounds of Formula (I), and methods for using the compounds of Formula (I) for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Abstract: A composition for forming a silica based layer includes a silicon-containing compound including polysilazane, polysiloxazane, or a combination thereof and one or more kinds of solvent, and having a turbidity increasing rate of less than or equal to about 0.13.